Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 148

1.

HIV Infection Is Associated With Downregulation of BTLA Expression on Mycobacterium tuberculosis-Specific CD4 T Cells in Active Tuberculosis Disease.

Barham MS, Abrahams DA, Khayumbi J, Ongalo J, Tonui J, Campbell A, de Kock M, Ouma SG, Odhiambo FH, Hanekom WA, Gandhi NR, Day CL.

Front Immunol. 2019 Aug 21;10:1983. doi: 10.3389/fimmu.2019.01983. eCollection 2019.

2.

Correction: Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort study.

Penn-Nicholson A, Hraha T, Thompson EG, Sterling D, Mbandi SK, Wall KM, Fisher M, Suliman S, Shankar S, Hanekom WA, Janjic N, Hatherill M, Kaufmann SHE, Sutherland J, Walzl G, De Groote MA, Ochsner U, Zak DE, Scriba TJ; ACS and GC6–74 cohort study groups.

PLoS Med. 2019 Jul 18;16(7):e1002880. doi: 10.1371/journal.pmed.1002880. eCollection 2019 Jul.

3.

New hope for tuberculosis vaccines.

Olesen OF, Abdullah F, Coppens R, Gardner PJ, Ginsberg AM, Hanekom WA, Laang H, Lewinsohn DM, Loots G, Schmidt A, Vekemans J, Voss GH.

Lancet Infect Dis. 2019 Jul;19(7):687-688. doi: 10.1016/S1473-3099(19)30280-4. No abstract available.

PMID:
31250810
4.

Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort study.

Penn-Nicholson A, Hraha T, Thompson EG, Sterling D, Mbandi SK, Wall KM, Fisher M, Suliman S, Shankar S, Hanekom WA, Janjic N, Hatherill M, Kaufmann SHE, Sutherland J, Walzl G, De Groote MA, Ochsner U, Zak DE, Scriba TJ; ACS and GC6–74 cohort study groups.

PLoS Med. 2019 Apr 16;16(4):e1002781. doi: 10.1371/journal.pmed.1002781. eCollection 2019 Apr. Erratum in: PLoS Med. 2019 Jul 18;16(7):e1002880.

5.

The way forward for tuberculosis vaccines.

White RG, Hanekom WA, Vekemans J, Harris RC.

Lancet Respir Med. 2019 Mar;7(3):204-206. doi: 10.1016/S2213-2600(19)30040-2. No abstract available. Erratum in: Lancet Respir Med. 2019 Apr;7(4):e15.

PMID:
30823973
6.

Toll-like receptor chaperone HSP90B1 and the immune response to Mycobacteria.

Graustein AD, Misch EA, Musvosvi M, Shey M, Shah JA, Seshadri C, Aguoju A, Bowman K, Mulenga H, Veldsman A, Hanekom WA, Hatherill M, Scriba TJ, Hawn TR.

PLoS One. 2018 Dec 14;13(12):e0208940. doi: 10.1371/journal.pone.0208940. eCollection 2018.

7.

Batf2 differentially regulates tissue immunopathology in Type 1 and Type 2 diseases.

Guler R, Mpotje T, Ozturk M, Nono JK, Parihar SP, Chia JE, Abdel Aziz N, Hlaka L, Kumar S, Roy S, Penn-Nicholson A, Hanekom WA, Zak DE, Scriba TJ, Suzuki H, Brombacher F.

Mucosal Immunol. 2019 Mar;12(2):390-402. doi: 10.1038/s41385-018-0108-2. Epub 2018 Dec 12.

PMID:
30542107
8.

Metabolite changes in blood predict the onset of tuberculosis.

Weiner J 3rd, Maertzdorf J, Sutherland JS, Duffy FJ, Thompson E, Suliman S, McEwen G, Thiel B, Parida SK, Zyla J, Hanekom WA, Mohney RP, Boom WH, Mayanja-Kizza H, Howe R, Dockrell HM, Ottenhoff THM, Scriba TJ, Zak DE, Walzl G, Kaufmann SHE; GC6-74 consortium.

Nat Commun. 2018 Dec 6;9(1):5208. doi: 10.1038/s41467-018-07635-7.

9.

PD-1 Expression on Mycobacterium tuberculosis-Specific CD4 T Cells Is Associated With Bacterial Load in Human Tuberculosis.

Day CL, Abrahams DA, Bunjun R, Stone L, de Kock M, Walzl G, Wilkinson RJ, Burgers WA, Hanekom WA.

Front Immunol. 2018 Aug 31;9:1995. doi: 10.3389/fimmu.2018.01995. eCollection 2018.

10.

Differential DNA methylation of potassium channel KCa3.1 and immune signalling pathways is associated with infant immune responses following BCG vaccination.

Hasso-Agopsowicz M, Scriba TJ, Hanekom WA, Dockrell HM, Smith SG.

Sci Rep. 2018 Aug 30;8(1):13086. doi: 10.1038/s41598-018-31537-9.

11.

Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection Trial.

Suliman S, Luabeya AKK, Geldenhuys H, Tameris M, Hoff ST, Shi Z, Tait D, Kromann I, Ruhwald M, Rutkowski KT, Shepherd B, Hokey D, Ginsberg AM, Hanekom WA, Andersen P, Scriba TJ, Hatherill M; H56-035 Trial Group.

Am J Respir Crit Care Med. 2019 Jan 15;199(2):220-231. doi: 10.1164/rccm.201802-0366OC.

PMID:
30092143
12.

Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination.

Nemes E, Geldenhuys H, Rozot V, Rutkowski KT, Ratangee F, Bilek N, Mabwe S, Makhethe L, Erasmus M, Toefy A, Mulenga H, Hanekom WA, Self SG, Bekker LG, Ryall R, Gurunathan S, DiazGranados CA, Andersen P, Kromann I, Evans T, Ellis RD, Landry B, Hokey DA, Hopkins R, Ginsberg AM, Scriba TJ, Hatherill M; C-040-404 Study Team.

N Engl J Med. 2018 Jul 12;379(2):138-149. doi: 10.1056/NEJMoa1714021.

13.

Four-gene Pan-African Blood Signature Predicts Progression to Tuberculosis.

Suliman S, Thompson E, Sutherland J, Weiner Rd J, Ota MOC, Shankar S, Penn-Nicholson A, Thiel B, Erasmus M, Maertzdorf J, Duffy FJ, Hill PC, Hughes EJ, Stanley K, Downing K, Fisher ML, Valvo J, Parida SK, van der Spuy G, Tromp G, Adetifa IMO, Donkor S, Howe R, Mayanja-Kizza H, Boom WH, Dockrell H, Ottenhoff THM, Hatherill M, Aderem A, Hanekom WA, Scriba TJ, Kaufmann SH, Zak DE, Walzl G; GC6-74 and ACS cohort study groups.

Am J Respir Crit Care Med. 2018 Apr 6. doi: 10.1164/rccm.201711-2340OC. [Epub ahead of print]

14.

Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial.

Penn-Nicholson A, Tameris M, Smit E, Day TA, Musvosvi M, Jayashankar L, Vergara J, Mabwe S, Bilek N, Geldenhuys H, Luabeya AK, Ellis R, Ginsberg AM, Hanekom WA, Reed SG, Coler RN, Scriba TJ, Hatherill M; TBVPX-114 study team.

Lancet Respir Med. 2018 Apr;6(4):287-298. doi: 10.1016/S2213-2600(18)30077-8.

PMID:
29595510
15.

Protein kinase C-delta (PKCδ), a marker of inflammation and tuberculosis disease progression in humans, is important for optimal macrophage killing effector functions and survival in mice.

Parihar SP, Ozturk M, Marakalala MJ, Loots DT, Hurdayal R, Beukes D, Van Reenen M, Zak DE, Mbandi SK, Darboe F, Penn-Nicholson A, Hanekom WA, Leitges M, Scriba TJ, Guler R, Brombacher F.

Mucosal Immunol. 2018 Mar;11(2):579-580. doi: 10.1038/mi.2017.108. Epub 2017 Dec 20.

PMID:
29346346
16.

Toward Tuberculosis Vaccine Development: Recommendations for Nonhuman Primate Study Design.

Laddy DJ, Bonavia A, Hanekom WA, Kaushal D, Williams A, Roederer M, Seder RA, Sharpe S, Verreck FAW, Darrah PA.

Infect Immun. 2018 Jan 22;86(2). pii: e00776-17. doi: 10.1128/IAI.00776-17. Print 2018 Feb.

17.

Sequential inflammatory processes define human progression from M. tuberculosis infection to tuberculosis disease.

Scriba TJ, Penn-Nicholson A, Shankar S, Hraha T, Thompson EG, Sterling D, Nemes E, Darboe F, Suliman S, Amon LM, Mahomed H, Erasmus M, Whatney W, Johnson JL, Boom WH, Hatherill M, Valvo J, De Groote MA, Ochsner UA, Aderem A, Hanekom WA, Zak DE; other members of the ACS cohort study team.

PLoS Pathog. 2017 Nov 16;13(11):e1006687. doi: 10.1371/journal.ppat.1006687. eCollection 2017 Nov.

18.

Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin for Infants of Human Immunodeficiency Virus-Infected Mothers: A Phase 2 Randomized, Controlled Trial.

Nemes E, Hesseling AC, Tameris M, Mauff K, Downing K, Mulenga H, Rose P, van der Zalm M, Mbaba S, Van As D, Hanekom WA, Walzl G, Scriba TJ, McShane H, Hatherill M; MVA029 Study Team.

Clin Infect Dis. 2018 Feb 1;66(4):554-563. doi: 10.1093/cid/cix834.

19.

Protein kinase C-delta (PKCδ), a marker of inflammation and tuberculosis disease progression in humans, is important for optimal macrophage killing effector functions and survival in mice.

Parihar SP, Ozturk M, Marakalala MJ, Loots DT, Hurdayal R, Maasdorp DB, Van Reenen M, Zak DE, Darboe F, Penn-Nicholson A, Hanekom WA, Leitges M, Scriba TJ, Guler R, Brombacher F.

Mucosal Immunol. 2018 Mar;11(2):496-511. doi: 10.1038/mi.2017.68. Epub 2017 Aug 9. Erratum in: Mucosal Immunol. 2017 Dec 20;:.

PMID:
28832027
20.

HIV-1 Infection Is Associated with Depletion and Functional Impairment of Mycobacterium tuberculosis-Specific CD4 T Cells in Individuals with Latent Tuberculosis Infection.

Day CL, Abrahams DA, Harris LD, van Rooyen M, Stone L, de Kock M, Hanekom WA.

J Immunol. 2017 Sep 15;199(6):2069-2080. doi: 10.4049/jimmunol.1700558. Epub 2017 Jul 31.

21.

Optimization and Interpretation of Serial QuantiFERON Testing to Measure Acquisition of Mycobacterium tuberculosis Infection.

Nemes E, Rozot V, Geldenhuys H, Bilek N, Mabwe S, Abrahams D, Makhethe L, Erasmus M, Keyser A, Toefy A, Cloete Y, Ratangee F, Blauenfeldt T, Ruhwald M, Walzl G, Smith B, Loxton AG, Hanekom WA, Andrews JR, Lempicki MD, Ellis R, Ginsberg AM, Hatherill M, Scriba TJ; C-040-404 Study Team and the Adolescent Cohort Study Team.

Am J Respir Crit Care Med. 2017 Sep 1;196(5):638-648. doi: 10.1164/rccm.201704-0817OC.

22.

Impact of isoniazid preventive therapy on the evaluation of long-term effectiveness of infant MVA85A vaccination.

Bunyasi EW, Luabeya AKK, Tameris M, Geldenhuys H, Mulenga H, Landry BS, Scriba TJ, Schmidt BM, Hanekom WA, Mahomed H, McShane H, Hatherill M.

Int J Tuberc Lung Dis. 2017 Jul 1;21(7):778-783. doi: 10.5588/ijtld.16.0709.

23.

Antigen Availability Shapes T Cell Differentiation and Function during Tuberculosis.

Moguche AO, Musvosvi M, Penn-Nicholson A, Plumlee CR, Mearns H, Geldenhuys H, Smit E, Abrahams D, Rozot V, Dintwe O, Hoff ST, Kromann I, Ruhwald M, Bang P, Larson RP, Shafiani S, Ma S, Sherman DR, Sette A, Lindestam Arlehamn CS, McKinney DM, Maecker H, Hanekom WA, Hatherill M, Andersen P, Scriba TJ, Urdahl KB.

Cell Host Microbe. 2017 Jun 14;21(6):695-706.e5. doi: 10.1016/j.chom.2017.05.012.

24.

A Functional Toll-Interacting Protein Variant Is Associated with Bacillus Calmette-Guérin-Specific Immune Responses and Tuberculosis.

Shah JA, Musvosvi M, Shey M, Horne DJ, Wells RD, Peterson GJ, Cox JS, Daya M, Hoal EG, Lin L, Gottardo R, Hanekom WA, Scriba TJ, Hatherill M, Hawn TR.

Am J Respir Crit Care Med. 2017 Aug 15;196(4):502-511. doi: 10.1164/rccm.201611-2346OC.

25.

The SIGLEC14 null allele is associated with Mycobacterium tuberculosis- and BCG-induced clinical and immunologic outcomes.

Graustein AD, Horne DJ, Fong JJ, Schwarz F, Mefford HC, Peterson GJ, Wells RD, Musvosvi M, Shey M, Hanekom WA, Hatherill M, Scriba TJ, Thuong NTT, Mai NTH, Caws M, Bang ND, Dunstan SJ, Thwaites GE, Varki A, Angata T, Hawn TR.

Tuberculosis (Edinb). 2017 May;104:38-45. doi: 10.1016/j.tube.2017.02.005. Epub 2017 Feb 21.

PMID:
28454648
26.

Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study.

Andrews JR, Nemes E, Tameris M, Landry BS, Mahomed H, McClain JB, Fletcher HA, Hanekom WA, Wood R, McShane H, Scriba TJ, Hatherill M.

Lancet Respir Med. 2017 Apr;5(4):282-290. doi: 10.1016/S2213-2600(17)30060-7. Epub 2017 Feb 16.

27.

Safety and Immunogenicity of Adenovirus 35 Tuberculosis Vaccine Candidate in Adults with Active or Previous Tuberculosis. A Randomized Trial.

van Zyl-Smit RN, Esmail A, Bateman ME, Dawson R, Goldin J, van Rikxoort E, Douoguih M, Pau MG, Sadoff JC, McClain JB, Snowden MA, Benko J, Hokey DA, Rutkowski KT, Graves A, Shepherd B, Ishmukhamedov S, Kagina BMN, Abel B, Hanekom WA, Scriba TJ, Bateman ED.

Am J Respir Crit Care Med. 2017 May 1;195(9):1171-1180. doi: 10.1164/rccm.201603-0654OC.

PMID:
28060545
28.

H1:IC31 vaccination is safe and induces long-lived TNF-α+IL-2+CD4 T cell responses in M. tuberculosis infected and uninfected adolescents: A randomized trial.

Mearns H, Geldenhuys HD, Kagina BM, Musvosvi M, Little F, Ratangee F, Mahomed H, Hanekom WA, Hoff ST, Ruhwald M, Kromann I, Bang P, Hatherill M, Andersen P, Scriba TJ; THYB04 study group.

Vaccine. 2017 Jan 3;35(1):132-141. doi: 10.1016/j.vaccine.2016.11.023. Epub 2016 Nov 18.

PMID:
27866772
29.

Bacillus Calmette-Guérin (BCG) Revaccination of Adults with Latent Mycobacterium tuberculosis Infection Induces Long-Lived BCG-Reactive NK Cell Responses.

Suliman S, Geldenhuys H, Johnson JL, Hughes JE, Smit E, Murphy M, Toefy A, Lerumo L, Hopley C, Pienaar B, Chheng P, Nemes E, Hoft DF, Hanekom WA, Boom WH, Hatherill M, Scriba TJ.

J Immunol. 2016 Aug 15;197(4):1100-1110. doi: 10.4049/jimmunol.1501996. Epub 2016 Jul 13.

30.

A Quantitative Analysis of Complexity of Human Pathogen-Specific CD4 T Cell Responses in Healthy M. tuberculosis Infected South Africans.

Lindestam Arlehamn CS, McKinney DM, Carpenter C, Paul S, Rozot V, Makgotlho E, Gregg Y, van Rooyen M, Ernst JD, Hatherill M, Hanekom WA, Peters B, Scriba TJ, Sette A.

PLoS Pathog. 2016 Jul 13;12(7):e1005760. doi: 10.1371/journal.ppat.1005760. eCollection 2016 Jul.

31.

Comparable CD4 and CD8 T cell responses and cytokine release after at-birth and delayed BCG immunisation in infants born in Australia.

Ritz N, Casalaz D, Donath S, Tebruegge M, Dutta B, Connell TG, Robins-Browne R, Britton WJ, Hanekom WA, Curtis N.

Vaccine. 2016 Jul 29;34(35):4132-4139. doi: 10.1016/j.vaccine.2016.06.077. Epub 2016 Jul 5.

PMID:
27396518
32.

Human newborn bacille Calmette-Guérin vaccination and risk of tuberculosis disease: a case-control study.

Fletcher HA, Filali-Mouhim A, Nemes E, Hawkridge A, Keyser A, Njikan S, Hatherill M, Scriba TJ, Abel B, Kagina BM, Veldsman A, Agudelo NM, Kaplan G, Hussey GD, Sekaly RP, Hanekom WA; BCG study team.

BMC Med. 2016 May 16;14:76. doi: 10.1186/s12916-016-0617-3.

33.

Corrigendum: T-cell activation is an immune correlate of risk in BCG vaccinated infants.

Fletcher HA, Snowden MA, Landry B, Rida W, Satti I, Harris SA, Matsumiya M, Tanner R, O'Shea MK, Dheenadhayalan V, Bogardus L, Stockdale L, Marsay L, Chomka A, Harrington-Kandt R, Manjaly-Thomas ZR, Naranbhai V, Stylianou E, Darboe F, Penn-Nicholson A, Nemes E, Hatherill M, Hussey G, Mahomed H, Tameris M, McClain JB, Evans TG, Hanekom WA, Scriba TJ, McShane H.

Nat Commun. 2016 May 6;7:11633. doi: 10.1038/ncomms11633. No abstract available.

34.

T-cell activation is an immune correlate of risk in BCG vaccinated infants.

Fletcher HA, Snowden MA, Landry B, Rida W, Satti I, Harris SA, Matsumiya M, Tanner R, O'Shea MK, Dheenadhayalan V, Bogardus L, Stockdale L, Marsay L, Chomka A, Harrington-Kandt R, Manjaly-Thomas ZR, Naranbhai V, Stylianou E, Darboe F, Penn-Nicholson A, Nemes E, Hatherill M, Hussey G, Mahomed H, Tameris M, McClain JB, Evans TG, Hanekom WA, Scriba TJ, McShane H.

Nat Commun. 2016 Apr 12;7:11290. doi: 10.1038/ncomms11290. Erratum in: Nat Commun. 2016 May 06;7:11633.

35.

A blood RNA signature for tuberculosis disease risk: a prospective cohort study.

Zak DE, Penn-Nicholson A, Scriba TJ, Thompson E, Suliman S, Amon LM, Mahomed H, Erasmus M, Whatney W, Hussey GD, Abrahams D, Kafaar F, Hawkridge T, Verver S, Hughes EJ, Ota M, Sutherland J, Howe R, Dockrell HM, Boom WH, Thiel B, Ottenhoff THM, Mayanja-Kizza H, Crampin AC, Downing K, Hatherill M, Valvo J, Shankar S, Parida SK, Kaufmann SHE, Walzl G, Aderem A, Hanekom WA; ACS and GC6-74 cohort study groups.

Lancet. 2016 Jun 4;387(10035):2312-2322. doi: 10.1016/S0140-6736(15)01316-1. Epub 2016 Mar 24.

36.

Evaluation of Xpert® MTB/RIF Assay in Induced Sputum and Gastric Lavage Samples from Young Children with Suspected Tuberculosis from the MVA85A TB Vaccine Trial.

Bunyasi EW, Tameris M, Geldenhuys H, Schmidt BM, Luabeya AK, Mulenga H, Scriba TJ, Hanekom WA, Mahomed H, McShane H, Hatherill M.

PLoS One. 2015 Nov 10;10(11):e0141623. doi: 10.1371/journal.pone.0141623. eCollection 2015.

37.

T Cell Responses against Mycobacterial Lipids and Proteins Are Poorly Correlated in South African Adolescents.

Seshadri C, Lin L, Scriba TJ, Peterson G, Freidrich D, Frahm N, DeRosa SC, Moody DB, Prandi J, Gilleron M, Mahomed H, Jiang W, Finak G, Hanekom WA, Gottardo R, McElrath MJ, Hawn TR.

J Immunol. 2015 Nov 15;195(10):4595-603. doi: 10.4049/jimmunol.1501285. Epub 2015 Oct 14.

38.

Risk of Disease After Isoniazid Preventive Therapy for Mycobacterium tuberculosis Exposure in Young HIV-uninfected Children.

Luabeya KK, Tameris MD, Geldenhuys HD, Mulenga H, Van Schalkwyk A, Hughes EJ, Toefey A, Scriba TJ, Hussey G, Mahomed H, McShane H, Landry B, Hanekom WA, Hatherill M.

Pediatr Infect Dis J. 2015 Nov;34(11):1218-22. doi: 10.1097/INF.0000000000000874.

39.

The Role of Clinical Symptoms in the Diagnosis of Intrathoracic Tuberculosis in Young Children.

Mulenga H, Tameris MD, Luabeya KK, Geldenhuys H, Scriba TJ, Hussey GD, Mahomed H, Landry BS, Hanekom WA, McShane H, Hatherill M.

Pediatr Infect Dis J. 2015 Nov;34(11):1157-62. doi: 10.1097/INF.0000000000000847.

40.

First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults.

Luabeya AK, Kagina BM, Tameris MD, Geldenhuys H, Hoff ST, Shi Z, Kromann I, Hatherill M, Mahomed H, Hanekom WA, Andersen P, Scriba TJ; H56-032 Trial Study Group, Schoeman E, Krohn C, Day CL, Africa H, Makhethe L, Smit E, Brown Y, Suliman S, Hughes EJ, Bang P, Snowden MA, McClain B, Hussey GD.

Vaccine. 2015 Aug 7;33(33):4130-40. doi: 10.1016/j.vaccine.2015.06.051. Epub 2015 Jun 19.

PMID:
26095509
41.

The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial.

Geldenhuys H, Mearns H, Miles DJ, Tameris M, Hokey D, Shi Z, Bennett S, Andersen P, Kromann I, Hoff ST, Hanekom WA, Mahomed H, Hatherill M, Scriba TJ; H4:IC31 Trial Study Group, van Rooyen M, Bruce McClain J, Ryall R, de Bruyn G; H4:IC31 Trial Study Groupa.

Vaccine. 2015 Jul 9;33(30):3592-9. doi: 10.1016/j.vaccine.2015.05.036. Epub 2015 Jun 3.

PMID:
26048780
42.

A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants.

Tameris M, Hokey DA, Nduba V, Sacarlal J, Laher F, Kiringa G, Gondo K, Lazarus EM, Gray GE, Nachman S, Mahomed H, Downing K, Abel B, Scriba TJ, McClain JB, Pau MG, Hendriks J, Dheenadhayalan V, Ishmukhamedov S, Luabeya AK, Geldenhuys H, Shepherd B, Blatner G, Cardenas V, Walker R, Hanekom WA, Sadoff J, Douoguih M, Barker L, Hatherill M.

Vaccine. 2015 Jun 9;33(25):2944-54. doi: 10.1016/j.vaccine.2015.03.070. Epub 2015 Apr 28.

43.

Mycobacterium tuberculosis-specific CD4 T cells are the principal source of IFN-γ in QuantiFERON assays in healthy persons.

Penn-Nicholson A, Nemes E, Hanekom WA, Hatherill M, Scriba TJ.

Tuberculosis (Edinb). 2015 May;95(3):350-1. doi: 10.1016/j.tube.2015.03.002. Epub 2015 Mar 10. No abstract available.

PMID:
25802032
44.

Tuberculosis vaccines: time for a global strategy.

Kaufmann SH, Evans TG, Hanekom WA.

Sci Transl Med. 2015 Feb 25;7(276):276fs8. doi: 10.1126/scitranslmed.aaa4730. No abstract available.

PMID:
25717094
45.

T cells and adaptive immunity to Mycobacterium tuberculosis in humans.

Jasenosky LD, Scriba TJ, Hanekom WA, Goldfeld AE.

Immunol Rev. 2015 Mar;264(1):74-87. doi: 10.1111/imr.12274. Review.

PMID:
25703553
46.

The dynamics of QuantiFERON-TB gold in-tube conversion and reversion in a cohort of South African adolescents.

Andrews JR, Hatherill M, Mahomed H, Hanekom WA, Campo M, Hawn TR, Wood R, Scriba TJ.

Am J Respir Crit Care Med. 2015 Mar 1;191(5):584-91. doi: 10.1164/rccm.201409-1704OC.

47.

Qualification of a whole blood intracellular cytokine staining assay to measure mycobacteria-specific CD4 and CD8 T cell immunity by flow cytometry.

Kagina BM, Mansoor N, Kpamegan EP, Penn-Nicholson A, Nemes E, Smit E, Gelderbloem S, Soares AP, Abel B, Keyser A, Sidibana M, Hughes JE, Kaplan G, Hussey GD, Hanekom WA, Scriba TJ.

J Immunol Methods. 2015 Feb;417:22-33. doi: 10.1016/j.jim.2014.12.003. Epub 2014 Dec 16.

48.

Differential leukocyte counting and immunophenotyping in cryopreserved ex vivo whole blood.

Nemes E, Kagina BM, Smit E, Africa H, Steyn M, Hanekom WA, Scriba TJ.

Cytometry A. 2015 Feb;87(2):157-65. doi: 10.1002/cyto.a.22610. Epub 2014 Dec 16.

49.

Safety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial.

Reither K, Katsoulis L, Beattie T, Gardiner N, Lenz N, Said K, Mfinanga E, Pohl C, Fielding KL, Jeffery H, Kagina BM, Hughes EJ, Scriba TJ, Hanekom WA, Hoff ST, Bang P, Kromann I, Daubenberger C, Andersen P, Churchyard GJ.

PLoS One. 2014 Dec 9;9(12):e114602. doi: 10.1371/journal.pone.0114602. eCollection 2014.

50.

Tuberculosis vaccines and prevention of infection.

Hawn TR, Day TA, Scriba TJ, Hatherill M, Hanekom WA, Evans TG, Churchyard GJ, Kublin JG, Bekker LG, Self SG.

Microbiol Mol Biol Rev. 2014 Dec;78(4):650-71. doi: 10.1128/MMBR.00021-14. Review.

Supplemental Content

Loading ...
Support Center